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ABSTRACT The identification of substrates of protein ty-
rosine phosphatases (PTPs) is an essential step toward a com-
plete understanding of the physiological function of members of
this enzyme family. PTPs are defined by a conserved catalytic
domain harboring 27 invariant residues. From a mutagenesis
study of these invariant residues that was guided by our knowl-
edge of the crystal structure of PTP1B, we have discovered a
mutation of the invariant catalytic acid (Asp-181 in PTP1B) that
converts an extremely active enzyme into a ‘‘substrate trap.’’
Expression of this D181Amutant of PTP1B in COS and 293 cells
results in an enzyme that competes with endogenous PTP1B for
substrates and promotes the accumulation of phosphotyrosine
primarily on the epidermal growth factor (EGF) receptor as well
as on proteins of 120, 80, and 70 kDa. The association between
the D181A mutant of PTP1B and these substrates was suffi-
ciently stable to allow isolation of the complex by immunopre-
cipitation. As predicted for an interaction between the substrate-
binding site of PTP1B and its substrates, the complex is dis-
rupted by vanadate and, for the EGF receptor, the interaction
absolutely requires receptor autophosphorylation. Furthermore,
from immunofluorescence studies, the D181A mutant of PTP1B
appeared to retain the endogenous EGF receptor in an intracel-
lular complex. These results suggest that the EGF receptor is a
bona fide substrate for PTP1B in vivo and that one important
function of PTP1B is to prevent the inappropriate, ligand-
independent, activation of newly synthesized EGF receptor in the
endoplasmic reticulum. This essential catalytic aspartate residue
is present in all PTPs and has structurally equivalent counter-
parts in the dual-specificity phosphatases and the low molecular
weight PTPs. Therefore we anticipate that this method may be
widely applicable to facilitate the identification of substrates of
other members of this enzyme family.
The protein tyrosine phosphatases (PTPs) are a structurally
diverse family of receptor-like and nontransmembrane en-
zymes that have been implicated in the control of numerous
physiological processes, including growth and differentiation
(1, 2). Approximately 75 PTPs have been identified to date.
These enzymes are characterized by the presence of a con-
served catalytic domain of '240 residues which contains the
unique signature motif, IVHCXAGXXR
S
TG, that defines this
enzyme family (3). The structural diversity is manifested by the
variability in noncatalytic sequences fused to the N or C
terminus of the catalytic domain. These noncatalytic segments
frequently serve a regulatory function, including ligand bind-
ing for receptor PTPs and targeting of cytoplasmic PTPs to
defined subcellular locations (1, 2).
Although great progress has been made in illustrating the,
somewhat unexpected, structural diversity within this large
enzyme family, relatively little is known of the physiological
function of individual PTPs. Presumably this structural diver-
sity reflects a broad range of functions for the PTP family in
vivo. To understand fully the function of PTPs, it will be
necessary to identify the physiological substrates of the indi-
vidual members of the family. However, progress in this area
to date has been limited. In this study, we have developed an
approach by which this may be achieved.
Our procedure was based on PTP1B, the prototypical PTP.
PTP1B was first purified from human placenta as a 37-kDa
protein of 321 amino acids constituting predominantly the cata-
lytic domain (4, 5). Isolation of cDNA illustrated that this purified
protein was derived from a full-length molecule of 435 residues,
containing a C-terminal regulatory segment fused to the catalytic
domain (6–8). The extreme C-terminal 35 residues constitute a
hydrophobic segment that is both necessary and sufficient for
targeting the enzyme to the cytoplasmic face ofmembranes of the
endoplasmic reticulum (9). This motif is preceded by a stretch of
hydrophilic residues that contains sites of serine phosphorylation;
PTP1B is phosphorylated in vivo in a manner that varies during
the cell cycle (10). We determined the crystal structure of the
37-kDa form of PTP1B, alone (11) and in a complex with a
peptide substrate (12). When the sequences of PTP catalytic
domains were aligned, a number of invariant residues were
identified. The structure of PTP1B illustrated that, for the most
part, these residues are clustered in regions of the protein
surrounding the active site, where they presumably facilitate
enzyme–substrate recognition and catalysis.
The signature motif functions as a phosphate-binding cradle in
which the catalytically essential cysteine (Cys-215 in PTP1B) is
positioned to act as a nucleophile to attack the phosphorus atom
of the phosphotyrosyl residue (pTyr) of the substrate (11, 13). In
PTP1B this motif lies at the base of a cleft on the surface of the
protein, defined at one end by Tyr-46 and the other by Phe-182.
The depth of this cleft is a primary determinant of the specificity
of the enzyme for pTyr. Upon substrate binding a localized
conformational change is induced in which the loop containing
Phe-182 moves 5.5 Å into the catalytic site, contributing to a
hydrophobic pocket that buries the pTyr of the substrate (12).
This conformational change positions the side chain of Asp-181
to act as a general acid to facilitate protonation of the phenolic
oxygen atom of the tyrosyl leaving group (12, 14). Cleavage of the
scissile bond yields a Cys-215 thiol-phosphate intermediate and
releases the free substrate protein product (15).Asp-181 then also
may serve to activate a water molecule responsible for hydrolysis
of the enzyme-phosphate intermediate (16).
We and others have shown that alteration of the nucleophilic
Cys to Ser or Ala allows some PTPs to be isolated in a complex
with their target substrates (12, 17–20). However, for other PTPs
this interaction is too weak to permit isolation of the complex.
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Thus it appears that the Cys3 SeryAla mutants may be limited
in their applicability and may not be utilized to isolate all
combinations of PTPs and substrates. In an attempt to generate
alternative ‘‘substrate-trapping’’ PTP mutants, we undertook a
systematic mutational analysis of the invariant residues that were
predicted from the crystal structure to be important in catalysis.
In this paper we report the identification and characterization of
such amutant form of PTP1B, in which Asp-181, the residue that
functions as a general acid to facilitate cleavage of the scissile
POO bond in the substrate, has been altered to Ala.
MATERIALS AND METHODS
Preparation and Assay of Mutants of PTP1B. Site-directed
mutagenesis of either the complete coding sequence of human
PTP1B or a clone encoding amino acids 1–321 (37-kDa PTP1B)
in pSK was accomplished by using the U-labeled template
method of Kunkel (21) and the Bio-Rad Muta-gene kit. For
expression ofmutants of 37-kDaPTP1B inEscherichia coli, DNA
fragments containing the mutation were exchanged with the
corresponding wild-type sequences in the T7-based expression
vector pET19b (Novagen) using the unique XhoI site at Arg-169
and either a 59 NcoI site or a 39 BamHI site. Similarly, an
XhoIyEcoRI fragment containing mutations in Cys-215 (M1 in
figures) or Asp-181 (M2 in figures) replaced the wild-type se-
quence in full-length PTP1B or the glutathione S-transferase
(GST)-PTP1B fusion protein in the pMT2 eukaryotic expression
vector (10). All subcloned fragments were sequenced completely
to confirm that no othermutations had been introduced.Mutants
of 37-kDa PTP1B were expressed in E. coli strain BL21 and
purified by chromatography on Fast Flow S-Sepharose andMono
Q (22).
Tyrosine phosphatase activity was measured using [32P]pTyr
reduced, carboxamidomethylated, and maleylated lysozyme
(RCML) as described previously (10). Kinetic parameters
were determined using a direct nonlinear curve-fitting routine.
Protein concentrations were determined by Bradford with a
bovine serum albumin standard (23).
Transfection, Immunoprecipitation, and Immunofluores-
cence. Calcium phosphate-mediated transfection of COS1 or 293
cells was performed with 20 mg of CsCl-purified DNA per 10-cm
dish of cells or 8 mg per 6-cm dish. The efficiency of transfection,
as assessed by 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-
Gal) staining of pSV-b-gal-transfected COS and 293 cells, was
16% and 20%, respectively. Cells were lysed 44–48 h after
transfection in 50 mM TriszHCl, pH 7.5y5 mM EDTAy150 mM
NaCly1% Triton X-100y5 mM iodoacetic acidy10 mM sodium
phosphatey10 mM NaFy5 mg/ml leupeptiny5 mg/ml aprotininy1
mM benzamidine (1 ml per 10-cm dish, 0.5 ml per 6-cm dish).
PTP1Bwas immunoprecipitated from lysates withmAbFG6 and
GST-PTP1B fusion proteins were precipitated with glutathione-
Sepharose, 4 mg of mAb or '10 ml of beads respectively per mg
of cell lysate. Precipitates were collected by centrifugation (15 s,
5000 3 g) at 48C, washed four times with 0.7 ml of ice-cold lysis
buffer, and finally heated at 958C for 5 min in 60 ml of 23
Laemmli sample buffer. mAbs to pTyr were used for immuno-
blotting at the following concentrations: 4G10 (Upstate Biotech-
nology) 1mgyml, RC20b (Transduction Laboratories) 0.5 mgyml,
G98 (Cold Spring Harbor Laboratory) 1:1000 dilution of ascites
fluid. mAb to epidermal growth factor (EGF) receptor (EGFR)
(Transduction Laboratories) was used at 1 mgyml and rabbit
polyclonal antisera to EGFR, #1964 and KSM (kindly provided
by G. Gill, University of California at San Diego), were used at
1:5000 and 1:1000 dilution, respectively. The levels of expression
of wild-type, C215A, and mutant PTP1B were always equivalent.
For immunofluorescence experiments, cells were seeded onto
glass coverslips at 2.5–33 105 per 6-cm dish, transfected with 10
mg of PTP1B cDNA, wild-type or mutant, and processed for
immunofluorescence staining at 36 h after transfection as previ-
ously described (24).
RESULTS
The goal of this study was to create mutant forms of PTP1B in
which the affinity for substrate remained similar to that of the
wild-type enzyme but in which catalytic activity had been re-
duced, to such an extent that an enzyme–substrate complex, once
formed, would be stable enough to withstand isolation. To
implement this we generated a series of point mutants in PTP1B,
expressed the proteins in E. coli, and purified them to homoge-
neity. The effects of these mutations on the ability of the enzyme
to dephosphorylate pTyr-RCML in vitro were then tested (Table
1).
In agreement with our predictions based on the x-ray structure
of PTP1B in complex with a substrate peptide, affinity for
substrate was significantly weakened by replacement of the
aromatic ring of Tyr-46 by Ser or Leu (Km increased by 20-fold)
or by loss of the electrostatic interaction betweenArg-221 and the
phosphate oxygens in Arg-2213Met. Whereas the Arg-2213
Lys mutant bound substrate normally, it has severely impaired
activity, suggesting that this invariant Arg in the signature motif
also has a critical catalytic role, most likely to stabilize the
transition state as proposed for YopH (25). As noted previously
by many groups, mutation of the active site Cys to Ala or Ser
inactivated the enzyme. In the context of our goal, mutation of
Asp-181 also dramatically reduced activity. Conversion of Asp-
181 to Glu reduced kcat'600-fold; however, the residual activity,
kcat5 3.6 min21, was sufficient to preclude the use of this mutant
as a substrate trap. In contrast, the kcat was reduced by a factor
of'105 in theD181Amutant, equivalent to'1 catalytic cycle per
hour. In this mutant one might anticipate that an enzyme–
substrate complex, further stabilized by chilling to 48C, would be
sufficiently long-lived to allow isolation.
To test the effects of PTP1B, and mutant forms thereof, on
the extent of tyrosine phosphorylation of proteins in vivo, we
expressed wild-type and C215A andD181Amutants of PTP1B
(either untagged or GST-tagged) in COS cells and immuno-
blotted cell lysates with an anti-pTyr antibody (Fig. 1). In cells
expressing mutant forms of PTP1B, we detected accumulation
of pTyr in several proteins, predominantly p180, and to lesser
extents p120 and p70. We also noted that the enhancement of
phosphorylation was more pronounced in cells expressing
D181A than C215A PTP1B. As expected, the level of tyrosine
phosphorylation in cells expressing the wild-type enzyme was
comparable to that in the vector control. These data suggest
that the mutant enzymes bind to and protect these proteins
from dephosphorylation by endogenous PTP1B.
To ascertain whether this interaction was stable to isolation,
wild-type and mutant forms of PTP1B were precipitated from
COS cell lysates, and associated proteins were visualized by
anti-pTyr immunoblotting (Fig. 2). The same proteins that
Table 1. Kinetic parameters of purified point mutants of 37-kDa








Wild type 60,200 102 2244
Tyr-46 3 Ser 4,120 1700 154
3 Leu 4,160 1700 155
Glu-115 3 Ala 5,700 45 212
3 Asp 5,900 20 220
Lys-116 3 Ala 68,600 150 2557
Lys-120 3 Ala 19,000 80 708
Asp-181 3 Ala 0.61 #126 0.023
3 Glu 97 10 3.6
His-214 3 Ala 700 20 26
Cys-215 3 Ser No detectable activity
Arg-221 3 Lys 11 80 0.41
3 Met 3.3 1060 0.12
Gln-262 3 Ala 720 9 27
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displayed enhanced phosphorylation were observed to copre-
cipitate with the mutant but not wild-type PTP1B, isolated
either by immunoprecipitation with mAb FG6 (untagged) or
by precipitation on glutathione-Sepharose (GST-tagged). Ex-
pression of GST-fusion proteins and precipitation with GSH-
Sepharose provides two advantages as compared with FG6
immunoprecipitations. These precipitates are cleaner to im-
munoblot because they do not contain any antibody and they
are free of any endogenous active PTP1B which exists as a
minor component in the FG6 immunoprecipitates. Once
again, greater quantities of the pTyr proteins coprecipitated
with the D181A mutant than the C215A mutant form of
PTP1B. Interestingly, the pattern of tyrosine phosphorylation
was the same before and after refeeding of serum-starved cells
(Fig. 2). These data suggest that the mutant PTPs are func-
tioning to protect the substrates against dephosphorylation by
endogenous phosphatases, thus increasing the basal phosphor-
ylation state. The importance of this observation is that it
indicates that the effects of the mutants are manifested
primarily within the cell and not after lysis.
To begin the process of identifying the proteins that display
enhanced phosphorylation and hence are potential substrates of
PTP1B, we starved COS cells of serum, then stimulated them
with either EGF or platelet-derived growth factor and examined
the patterns of tyrosine phosphorylation that were induced, by
immunoblotting lysates with an anti-pTyr antibody.Most notably,
in response to EGF the phosphorylation state of a 180-kDa
protein, presumably the EGFR, was markedly enhanced. This
protein comigrated with pTyr-p180 that coprecipitates with mu-
tant PTP1B (Fig. 2). When this experiment was repeated in 293
cells, which possessmuch lower levels of endogenous EGFR, only
trace quantities of p180 were detected in association with D181A
PTP1B. However p120, p70, and an additional pTyr protein of
'80 kDa were observed to coprecipitate with the mutant PTP
(data not shown). We tested further the possibility that p180 was
the EGFR by expressing wild-type and mutant forms of PTP1B
in COS cells and, after serum starvation, examining the effects of
EGF treatment on the patterns of tyrosine phosphorylation (Fig.
3). A comparison of immunoblots of the PTP1B precipitates
using either anti-pTyr or anti-EGFR antibodies indicates that
p180 is the EGFR. Again, PTP1B-D181A appeared to be more
efficient at precipitating the EGFR than C215A, and no associ-
ation was observed with the wild-type enzyme. Despite the fact
that the total cellular content of EGFR was not altered by
treatment with EGF, more EGFR was precipitated by PTP1B-
D181A after administration of the growth factor. Moreover,
more pTyr-p180 protein coprecipitated with the mutant PTP
after growth factor treatment, consistent with the concept that
EGF-induced autophosphorylation of its receptor produced
higher levels of substrate available for trapping.
We examined whether the interaction between PTP1B and
EGFR involved the catalytic site of the phosphatase by
investigating the dependence upon tyrosine phosphorylation
of the substrate. Wild-type EGFR or mutant forms, either
inactivated as a protein tyrosine kinase or from which the sites
of autophosphorylation had been eliminated, were coex-
pressed in 293 cells with the various forms of PTP1B, and
PTP1B immunoprecipitates were blotted with either anti-
EGFR or anti-pTyr antibodies (Fig. 4). Although the various
forms of the EGFR were expressed to similar levels, associa-
tion was observed only between the wild-type EGFR and the
substrate-trapping mutants of PTP1B. These data established
that tyrosine phosphorylation of the EGFR was required for
the interaction. Furthermore, treatment with pervanadate, a
PTP inhibitor that covalently modifies the nucleophilic Cys
(26), disrupted complex formation between PTP1B-D181A
and EGFR (data not shown). These observations suggest that
this association represents an enzyme–substrate interaction.
FIG. 1. Induction of tyrosine phosphorylation resulting from ex-
pression of PTP1B mutants in COS cells. Samples (50 mg) of protein
from lysates of COS cells transfected with pMT2 alone (vector) or with
pMT2 plasmids expressing wild-type PTP1B, PTP1B with a C215A
mutation (M1), PTP1B with a D181A mutation (M2), or GST fusions
of each of these proteins were immunoblotted with anti-phosphoty-
rosine mAb 4G10. Proteins showing substantial increases in their
phosphotyrosine content are marked with the dark arrows on the left.
The positions of the molecular mass markers (Sigma) myosin, b-ga-
lactosidase, phosphorylase, bovine serum albumin, ovalbumin, and
carbonic anhydrase are marked on the right with thin arrows.
FIG. 2. Precipitation of tyrosine-phosphorylated proteins in associ-
ation with the D181A (M2) mutant of PTP1B. Immunoprecipitates of
PTP1B from lysates of COS cells transfected to express PTP1B, C215A
(M1), or D181A (M2) and glutathione-Sepharose precipitates from
lysates of COS cells transfected to express GST fusions to each of these
proteins were immunoblotted with anti-phosphotyrosine mAb 4G10.
Pairs of lanes represent samples from duplicate transfections. A 2
indicates that for 24 h prior to harvesting the cells were maintained in
media without serum. Lanes marked with1 indicate that these cells were
similarly deprived of serum until 10 min before harvesting, during which
time they were incubated with 20% fetal bovine serum, a treatment that
did not significantly alter the phosphotyrosine content of proteins asso-
ciated withD181A-PTP1B. The three intense black bands found in all the
anti-PTP1B immunoprecipitates, including the vector only control, are
derived from the precipitating mAb. (Right) Anti-pTyr (4G10) blot of 50
mg of lysate from untransfected COS cells that were untreated (none) or
incubated for 10 min with EGF at 100 ngyml or platelet-derived growth
factor (PDGF) at 5 ngyml.
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In addition, we have examined the association between EGFR
and the substrate-trapping mutants of PTP1B by immunofluo-
rescence as an independent confirmation that the association
occurred in vivo and not after lysis (Fig. 5). Wild-type or C215A
PTP1B exhibited a reticular pattern of staining extending from
the nucleus throughout the cell, as expected for a protein targeted
to the endoplasmic reticulum (Fig. 5A). In comparison, the
staining of endogenous EGFR appeared diffuse in cells coex-
pressing wild-type or C215A PTP1B, which display little or no
association with the protein tyrosine kinase(Fig. 5B). In contrast,
the staining of the EGFR was altered in cells coexpressing
PTP1B-D181A and exhibited a distinct punctate appearance that
was not detected in surrounding cells that failed to express the
mutant PTP (Fig. 5D). In these PTP1B-D181A-expressing cells,
this punctate appearance of anti-EGFR staining precisely
matched foci of intense staining with the anti-PTP1B antibody
FG6 (Fig. 5C). This coincidence of EGFR staining with PTP1B-
D181A, the substrate-trapping mutant that affords greatest pro-
tection and ability to coprecipitate the EGFR, reinforces the
interpretation that the association occurred in a cellular context
rather than in the lysate. It also suggests that in cells expressing
PTP1B-D181A mutants, the intracellular location of the EGFR
may be determined by colocalization with PTP1B as a result of
‘‘substrate trapping.’’
Although these data illustrate an association between sub-
strate-trapping mutants of PTP1B and EGFR, it was impor-
tant to test whether such an interaction would be observed
after the expression of the equivalent mutant form of another
member of the PTP family. Thus we examined the state of
basal phosphorylation of tyrosyl residues in proteins fromCOS
cells that had been serum starved after expression of wild-type
and mutant PTP1B or the equivalent forms of another cyto-
plasmic PTP, PTP-PEST (27). Whereas in the presence of
PTP1B-D181A the EGFR exhibits enhanced phosphorylation,
no such effect was observed after expression of either PTP-
PEST C231S or D199A (Fig. 6). Subsequent studies have
revealed that PTP-PEST displays a distinct substrate specific-
ity, showing a high degree of selectivity for p130cas as a target
substrate (27). This result suggests that individual PTPs display
specificity in their interaction with substrates in the cell.
DISCUSSION
The diversity in structural motifs that have been observed in
members of the PTP family is suggestive of important roles in the
control of a broad range of fundamental physiological signaling
events. Clearly, a definition of the spectrum of phosphotyrosyl
proteins dephosphorylated by an individual PTP in vivo will be a
prerequisite for the elucidation of the physiological function of
that enzyme. In this paper we describe a method by which such
substrate identification may be achieved.
Mutants of some members of the PTP family in which the
catalytically essential nucleophilic Cys residue from the signature
motif has been mutated to Ser or Ala are inactive but retain the
ability to bind to substrate in vitro. For example, we used a Cys3
Ser mutant form of PTP1B to determine the crystal structure of
the enzyme–substrate complex (12), and binding of this mutant
to autophosphorylated EGFR in vitro has been examined (19). In
addition, there are examples in which such mutants have been
shown to bind to substrate in vivo, including MKP-1 (17), YopH
(28), and theDrosophila SH2 domain PTP csw (29). However, in
some of these cases it is not clear that the interaction is mediated
solely by the inactivated catalytic domain (28, 29). In our expe-
rience such mutant PTPs do not uniformly bind to substrates in
a stable manner in the cell. In this paper we have demonstrated
that a mutant of PTP1B in which the invariant aspartate, Asp-
181, which functions as a general acid in protonating the tyrosyl
leaving group of the substrate, is changed to Ala, retains the
ability to bind to substrates in a cellular context but is markedly
FIG. 3. Identification of tyrosine-phosphorylated p180 in the D181A
precipitates as the EGFR. This experiment was conducted as described
in the legend of Fig. 2 except that the resulting immunoprecipitates were
split in half, subjected to electrophoresis on duplicate SDSy
polyacrylamide gels, and blotted with either anti-EGFR mAb (Trans-
ductionLaboratories) (Upper Left) or with anti-pTyr (4G10) (Lower Left).
Pairs of lanes represent samples from duplicate transfections. A 2
indicates that for 24 h prior to harvesting the cells were maintained in
media without serum. A 1 indicates that these cells were similarly
deprived of serum until 10 min before harvesting, during which time they
were incubated with EGF at 100 ngyml. The anti-pTyr blot was deliber-
ately overexposed in an attempt to observe pTyr-containing proteins in
the C215A (M1) precipitates and to visualize p70 and p80 in the D181A
(M2) precipitates. Anti-EGFR staining was weaker than anti-pTyr stain-
ing of p180 in D181A (M2) precipitates, presumably either because the
anti-EGFR antibody is of lower affinity or because there are multiple
pTyr epitopes recognized by 4G10 in the ‘‘trapped’’ EGFR. (Right)
Anti-EGFRblot of 50mg of lysate fromuntransfectedCOScells thatwere
untreated (2) or incubated for 10 min with EGF at 100 ngyml (1).
FIG. 4. Reconstitution of the interaction between D181A and the
EGFR requires EGFR autophosphorylation. 293 cells were cotrans-
fected with plasmids expressing PTP1B, the C215A or D181A PTP1B
mutants, and plasmids expressing the human EGFR or a catalytically
inactive (K2) mutant, in which the Lys responsible for coordinating
ATP, Lys-721, was converted to Arg, or a C-terminally truncated
(c9958) form that lacks all the major autophosphorylation sites.
Immunoprecipitates of PTP1B were split in half and resolved by
SDSyPAGE on duplicate gels. One gel (Upper) was blotted with
anti-EGFR antibody KSM and the other (Lower) was blotted for pTyr
with G98. Panels on each end represent immunoblots of 50 mg of lysate
from the cells cotransfected with D181A-PTP18 (M2) and the various
EGFR forms. CMV, cytomegalovirus. Although both the K2 and
c9958 forms of EGFR are expressed well, neither contains pTyr, and
both fail to interact with the D181A mutant of PTP1B.
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attenuated in its catalytic function. Thus the enzyme–substrate
complex is stabilized sufficiently to permit isolation. In compar-
ison, although the C215A mutant traps the same spectrum of
pTyr proteins as PTP1B-D181A, it does so at much lower
efficiency. Similar data have been obtained subsequently for
PTP-PEST and its substrate, p130cas (27).
There are two features of the PTP1B-D181A mutant that
may contribute to its enhanced substrate-trapping properties
relative to PTP1B-C215A. First, the dephosphorylation reac-
tion catalyzed by PTPs proceeds via the formation of a
cysteinyl phosphate intermediate, generated after nucleophilic
attack by the active-site Cys upon the phosphorus atom of the
substrate (15). This is accompanied by cleavage of the POO
bond between the phosphorus and the phenolic oxygen of the
tyrosyl side chain in the substrate, mediated by the invariant
aspartate. Thus, in the absence of this acidic residue one would
anticipate that POO bond cleavage would be suppressed,
thereby potentially stabilizing the interaction with the active-
site Cys. Stabilization of the complex may be further facilitated
by hydrophobic interactions between the residues lining the
substrate-binding pocket of the enzyme and the tyrosyl side
chain of the substrate that are induced after the loop closure
that accompanies substrate binding (12). Second, the mutation
of Asp-181 to an uncharged residue, Ala, will result in a
decrease in negative charge at this position. Thus the potential
for electrostatic repulsion between the negatively charged side
chain of Asp-181 and the negatively charged phosphate moi-
ety, which would occur in the PTP1B-C215SyA mutants,
would be reduced in PTP1B-D181A. Again this may favor loop
closure and stabilization of the enzyme–substrate complex.
Considering that the substrate-trapping mutant PTPs have the
ability, through interaction with pTyr residues, to increase the
basal phosphorylation of their target substrates, onemight expect
them to promote ligand-independent signaling. However because
these mutants form stable complexes with target substrates, they
may also interfere with signaling in vivo in a manner analogous to
the wild-type phosphatase. Thus if the site of tyrosine phosphor-
ylation on the substrate is critical for a protein–protein interaction
required for signaling or if the substrate is an enzyme and the
phosphorylation site is located close to the active site, steric
hindrance resulting frombinding of themutant PTPmay exert an
effect that is functionally equivalent to dephosphorylation. Thus,
for many PTPs Cys3 SeryAla (or Asp3Ala) mutants may not
be an appropriate choice as ‘‘inactive’’ controls for effects of
expression of wild-type enzymes. Consideration of the data in
Table 1 suggests that mutations in the invariant Arg in the
signaturemotif, Arg-221 in PTP1B, which abrogate both catalytic
activity and affinity for substrate, might be better suited to this
purpose. This Arg residue normally functions in electrostatic and
hydrogen-bonding interactions with the phosphate moiety of the
substrate and functions to stabilize the transition state (25).
The successful application of this technique to identify
additional substrates of PTP1B, and substrates of other PTPs,
will require expression of the Asp3 Ala mutant PTP in cells
and selection of an appropriate stimulus to trigger tyrosine
phosphorylation of the substrate and accumulation of a com-
plex with the mutant phosphatase. For PTP1B, EGFR is
naturally abundant in COS cells, and its basal rate of auto-
phosphorylation generated enough tyrosine-phosphorylated
protein to be trapped by PTP1B-D181A and to be detected by
anti-pTyr immunoblotting. Its high molecular weight, charac-
FIG. 5. Colocalization of D181A-PTP1B and endogenous EGFRs. COS 1 cells transfected with wild-type PTP1B (data not shown) or C215A
(A and B) or D181A expression plasmids (C and D) were fixed with paraformaldehyde at 36 h after transfection and processed for
immunofluorescence as previously described (24). Cells were incubated with anti-PTP1B FG6 ascites fluid (10) and anti-EGFR polyclonal serum
(1964, kindly provided by G. Gill) at dilutions of 1y4000 and 1y500, respectively. Overexpressed PTP1B (A and C) and endogenous EGFR (B and
D) were visualized with fluorescein-conjugated sheep anti-mouse and Texas red-conjugated goat anti-rabbit antibodies (Cappel), respectively.
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teristic of growth factor receptors, facilitated identification. Of
the less-phosphorylated substrates of PTP1B, the finding that
phosphorylation of p70 is enhanced upon cotransfection with
v-src and D181A may enable enough of this substrate to be
isolated to allow its identification by peptide sequencing. In
contrast, the substrate of PTP-PEST, p130cas, although rela-
tively abundant in COS cells, does not accumulate in a
tyrosine-phosphorylated state that is trapped by PTP-PEST-
D199A in unstimulated cells (27). However, treatment of cells
with pervanadate, or less potently by cotransfection of v-src,
elevates phosphorylation of p130cas to levels that enable it to
be trapped specifically by D199A-PTP-PEST and readily
detected by anti-pTyr blotting (27). In addition to the use of
these trapping mutants to identify substrates, it also may be
possible to identify the site within the cell at which a PTP acts
on a particular target, through colocalization of the substrate
and the Asp3Ala mutant PTP. Thus, whereas we expect that
the application of Asp 3 Ala mutants of other PTPs will be
generally useful, the precise experimental approach and choice
of cells to study will vary with each individual phosphatase.
There is a considerable body of data in the literature to
indicate that PTP1B is somewhat promiscuous in its substrate
preference in vitro, dephosphorylating a wide variety of protein
and peptide substrates, albeit with widely varying Km values (5,
30, 31). However, the use of the PTP1B-D181A substrate-
trapping mutant described in this paper has revealed that
within the cell this activity is constrained. PTP1B selected a
small number of substrates from the plethora of available pTyr
proteins. The major substrate detected was the EGFR, to-
gether with no more than three additional proteins, p120, p80,
and p70. Our data suggest that PTP1B may exert its effects on
newly synthesized EGFRs, preventing inappropriate, ligand-
independent, signaling by nascent receptors in transit through
the endoplasmic reticulum. The identity of the other substrates
remains unclear at present. Using their apparent molecular
weights to predict identity, we have tested but failed to detect
cross-reactivity between these proteins and antibodies to FAK,
p120cas, c-cbl, Src, raf-1, paxillin, p62, or SHP2 in PTP1B-
D181A precipitates with antibodies that readily detected these
proteins in cell lysates (A.J.F. and N.K.T., unpublished re-
sults). In 293 cells expressing v-Src together with PTP1B-
D181A, we did not detect phosphorylation of the EGFR but
noted that the substrate-trapping mutant interacted selectively
with a 70-kDa protein from the greatly increased spectrum of
tyrosyl-phosphorylated proteins (data not shown). Interest-
ingly, Dixon’s group reported that dephosphorylation of ty-
rosyl residues in a 70-kDa protein was the major change in
phosphorylation observed in v-Src-transformed cells overex-
pressing PTP1B (32). However, the identity of this protein
remains unclear. Nevertheless, the data further reinforce the
importance of targeting PTPs to defined subcellular locations
as a mechanism for control of substrate specificity.
In summary, these data highlight the fact that PTP1B can
display substrate specificity in vivo and bolster the hypothesis that
subcellular targeting is an important mechanism by which such
specificity is achieved. The substrate-trapping mutant described
in this paper is altered in a residue that is an invariant catalytic
acid in all members of the PTP family. Therefore the use of this
mutation should be generally applicable to any PTP and may
represent a powerful tool with which to delineate the physiolog-
ical substrate specificity of other members of the family, thereby
revealing important insights into their function in vivo.
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FIG. 6. The analogous substrate-trapping mutant in PTP-PEST does
not interact with the EGFR. This figure shows an anti-pTyr blot (RC20b)
of precipitates prepared from lysates of COS cells that were transfected
to express PTP1B, the C215A-PTP1B mutant (M1), the D181A-PTP1B
mutant (M2), the GST fusions of these proteins, or PTP-PEST and the
analogous mutants of it: C231S-PTP-PEST (M1) or D199A-PTP-PEST
(M2). PTP-PEST was immunoprecipitated with mAb AG25 (27). The
expression levels of the PTP-PEST proteins were similar to those for
PTP1B.
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